Tuesday, August 18, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for DiagnosticstodayCRYPTOT. Rowe Price's Active Multi-Token Crypto ETF Is a Fee Story — and a Pressure Test for Bitwise and Grayscale4 weeks agoHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records MonopolytodayHEALTHCARE & FDACMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient Rivals4 weeks agoDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor WindfalltodayWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes the Pecking Order — Microsoft and Oracle Gain, Open-Source Loses4 weeks agoENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input EasestodayWHITE HOUSEWhite House Cybersecurity Clearinghouse Creates a Direct Revenue Line for CrowdStrike, Palantir, and Microsoft4 weeks agoWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma DemandyesterdayHEALTHCARE & FDACMS's Site-Neutral and 340B Reform Proposal Squeezes Hospital Margins and Lifts Independent Pharmacies4 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face PressureyesterdayDEFENSEU.S.-Iran Escalation and a Stalled Strait of Hormuz Are a Windfall for Tanker Owners and Defense Primes4 weeks agoTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings BoostyesterdayWHITE HOUSEWhite House Control Over Frontier AI Access Reshapes Who Wins the Model Race4 weeks agoENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Path2 days agoENERGYNew Mexico's Pipeline Denial Puts Oracle's Data Center Expansion on Ice — and Highlights Every Hyperscaler's Power Risk4 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings2 days agoTECHBosch's $225M CHIPS Award for Silicon Carbide Chips Is a Direct Threat to Wolfspeed's U.S. Market Share4 weeks agoCRYPTOSEC Delays Crypto Rules—Uncertainty Persists3 days agoDEFENSEU.S.-Iran Conflict Escalation Stalls Hormuz Shipping — Defense Contractors and Oil Majors Are the Immediate Read4 weeks agoTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refund3 days agoDEFENSEPentagon's $80M Drone Defense Contract Points to the Counter-UAS Names Worth Watching4 weeks agoTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makers3 days agoENERGYNew Jersey's Nuclear Energy Law Opens a Real Revenue Path for Small Reactor Developers4 weeks agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins4 days agoWHITE HOUSETrump's Defense Supply Chain Order Tightens Waiver Rules — Domestic Parts Makers Win, Foreign-Sourced Primes Face Friction4 weeks agoDEFENSEBlackSky Lands Multi-Year Satellite Contract4 days agoCRYPTOWhite House Concedes Ethics Provision in Crypto Bill — Clearing the Last Roadblock for Stablecoin Legislation4 weeks agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility5 days agoTECHBosch's $225M CHIPS Act Award for Roseville Chips Away at U.S. Dependence on Asian Auto Semiconductors4 weeks agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract5 days agoWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Defense Supply Chain — and Sends Money to U.S. Miners4 weeks agoHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock6 days agoHEALTHCARE & FDACMS Freezes $1 Billion in Medicaid Payments to California and Minnesota — Managed Care Insurers Face Revenue Gaps4 weeks agoENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask6 days agoENERGYTrump's Saudi Nuclear Pact Without Enrichment Safeguards Heads to Congress — U.S. Uranium and Nuclear Services Names Are the Play4 weeks agoHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance6 days agoENERGYNRC Approves Holtec's Upgraded Spent Fuel Storage System — A Quiet Win for Nuclear's Capacity Expansion4 weeks agoWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing6 days agoTRADE & TARIFFSTrump's 50% Canada Tariff Threat Keeps U.S. Aluminum Tight — Domestic Producers Win, Manufacturers Pay4 weeks agoWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shiftlast weekDEFENSEHouse Passes $1.15T Defense Bill — Missile Defense, Shipbuilding, and Next-Gen Air Get the Money4 weeks agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gainslast weekCRYPTOThe Senate's Landmark Crypto Bill Creates Winners Inside the ETF and Exchange Stack4 weeks agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertaintylast weekWHITE HOUSETrump's Critical Minerals Order Cuts China Out of the Military Supply Chain — These Miners Fill the Gap4 weeks agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfoliolast weekDEFENSEOracle Lands a $7B Pentagon Software Contract — and the Market Should Take It Seriously4 weeks agoDEFENSEPentagon Awards Space-Based Target Tracking Contractslast weekDEFENSEThe U.S.-Iran War Is Costing $37.5B and Counting — Here's Where That Money Goes4 weeks agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakeslast weekENERGYTrump Signs the Saudi Nuclear Deal — and U.S. Uranium and Reactor Companies Are the Quiet Winners4 weeks agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employerslast weekMARKETSChina's $765M Antitrust Fine on Trip.com Is a Warning Shot for U.S.-Listed Chinese Consumer Stocks3 weeks agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backinglast weekTRADE & TARIFFSTariffs on Indian Pharma Are Coming — and U.S. Generic Drug Buyers Will Pay the Bill3 weeks agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payoutlast weekHEALTHCARE & FDACMS's Star Ratings Overhaul Rescues the Biggest Medicare Advantage Insurers — For Now3 weeks agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanomalast weekDEFENSEPentagon's $7B Oracle Software Deal Is One of the Cleanest Defense-Tech Wins in Years3 weeks agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practiceslast weekDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Direct Win for Oracle, Pressure on Smaller Defense IT Rivals3 weeks agoMARKETSFTC Threatens Booking Holdings Over Priceline Practiceslast weekTECHFCC Tightens Submarine Cable Licensing Rules—Tech Giants Face New Compliance Costs, Telecom Carriers Gain Regulatory Clarity3 weeks agoDEFENSERising Defense Spending Lifts Northrop Grumman Outlooklast weekHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—UnitedHealth, Humana, and Anthem Positioned to Gain from Simplified Metrics3 weeks agoTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestonelast weekDEFENSEHouse Passes $1.15 Trillion Defense Bill—Lockheed, Raytheon, and General Dynamics Positioned for Record Spending3 weeks agoHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relieflast weekDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Largest Defense IT Overhaul in Years3 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressurelast weekDEFENSERocket Lab Wins $266M Space Force Contract—Suborbital Launch Capability Becomes Defense Asset3 weeks agoHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Winlast weekHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—Big Insurers Win, Quality Metrics Tighten3 weeks agoTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeezelast weekDEFENSERocket Lab Wins $266M Space Force Missile Defense Contract—Suborbital Launch Niche Gets Federal Validation3 weeks agoENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risk2 weeks agoDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Cloud Incumbents Face Pressure, Oracle Locks in Defense Revenue3 weeks agoHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption2 weeks agoCRYPTOSEC Settles Coinbase FOIA Suit Over Missing Gensler Texts—Crypto Compliance Pressure Eases, Coinbase Stock Gains Clarity3 weeks agoWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market2 weeks agoHEALTHCARE & FDACMS Stars Redo Lifts Medicare Advantage Insurers—Rating System Overhaul Favors UnitedHealth, Humana, Anthem3 weeks agoDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue2 weeks agoDEFENSEPentagon Awards Largest F-35 Spare Parts Contract—Lockheed Locks in Sustainment Revenue3 weeks agoHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win2 weeks agoDEFENSEHouse Passes $1.15T Defense Bill—Lockheed, Raytheon, General Dynamics Lock in Revenue3 weeks agoTECHCommerce Awards $874M in Semiconductor R&D LOIs—Chip Makers Get Federal Backing2 weeks agoMARKETSSEC Explores 23-Hour Stock Trading—Market Makers and Tech Platforms Get New Revenue3 weeks agoTRADE & TARIFFSAmazon Gets $600M Tariff Refund—Retailers Lift Guidance on Windfall2 weeks agoENERGYPHMSA Updates Pipeline Safety Standards—Compliance Costs Hit Operators, Benefit Inspectors3 weeks agoSEARCH DEMANDData Center Power Exchange2 weeks agoSEARCH DEMANDCasgevy List Price: $2.2 Million2 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

FDA Reclassifies Cancer Tests—Easier Path for Diagnostics

In situ hybridization devices move from premarket approval to special controls, cutting regulatory friction.

Image: Money Racket
By at Money Racket · Aug 18, 2026

The FDA reclassified in situ hybridization (ISH) test systems used with approved oncology drugs from Class III (premarket approval) to Class II (special controls), subject only to premarket notification. This streamlines the approval pathway for diagnostic makers seeking to bring ISH tests to market alongside existing cancer therapies.

Reclassification cuts regulatory friction, letting diagnostic makers bring oncology tests to market faster and cheaper.

Who cashes in: Diagnostic device makers and IVD companies that develop ISH tests benefit from lower regulatory burden and faster time-to-market. Larger players like Roche (RHHBY) and Agilent (A) already operate in companion diagnostics; the reclassification reduces approval friction for their next-generation ISH platforms. Smaller pure-play diagnostic firms—particularly those focused on oncology companion diagnostics—see a clearer path to revenue without the cost and delay of full premarket approval. Pathology labs and hospital systems that adopt these tests gain faster access to precision oncology tools.

Who's exposed: No direct losers here. The reclassification does not disrupt existing approved tests or create new competition for established players; it simply lowers the bar for new entrants. Incumbent diagnostic suppliers face slightly more competition, but the overall market expands as adoption accelerates.

What to watch next: Watch for new ISH test launches from mid-cap diagnostic firms over the next 12–18 months. Track Roche and Agilent earnings calls for commentary on companion diagnostic pipeline acceleration. Monitor hospital pathology adoption rates and reimbursement coding updates from CMS, which will signal whether payers are ready to cover these tests at scale.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/fda-reclassifies-ish-oncology-tests-lower-barrier/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →